KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Intangibles (2016 - 2020)

Pfizer (PFE) has disclosed Change in Intangibles for 8 consecutive years, with $38.0 million as the latest value for Q3 2020.

  • On a quarterly basis, Change in Intangibles fell 60.82% to $38.0 million in Q3 2020 year-over-year; TTM through Sep 2020 was $125.0 million, a 73.35% decrease, with the full-year FY2020 number at $539.0 million, up 28.95% from a year prior.
  • Change in Intangibles was $38.0 million for Q3 2020 at Pfizer, up from $1.0 million in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $158.0 million in Q1 2019 to a low of $1.0 million in Q2 2020.
  • A 5-year average of $74.1 million and a median of $76.5 million in 2016 define the central range for Change in Intangibles.
  • Peak YoY movement for Change in Intangibles: surged 1820.0% in 2016, then crashed 99.08% in 2020.
  • Pfizer's Change in Intangibles stood at $80.0 million in 2016, then decreased by 8.75% to $73.0 million in 2017, then skyrocketed by 43.84% to $105.0 million in 2018, then crashed by 48.57% to $54.0 million in 2019, then dropped by 29.63% to $38.0 million in 2020.
  • Per Business Quant, the three most recent readings for PFE's Change in Intangibles are $38.0 million (Q3 2020), $1.0 million (Q2 2020), and $32.0 million (Q1 2020).